Moderna (MRNA) Enterprise Value (2016 - 2025)
Moderna (MRNA) has disclosed Enterprise Value for 9 consecutive years, with -$5.8 billion as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 17.45% to -$5.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.8 billion, a 17.45% increase, with the full-year FY2025 number at -$5.8 billion, up 17.45% from a year prior.
- Enterprise Value was -$5.8 billion for Q4 2025 at Moderna, down from -$4.5 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.9 billion in Q2 2022 to a low of -$10.7 billion in Q4 2021.
- A 5-year average of -$6.5 billion and a median of -$6.4 billion in 2024 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: tumbled 535.07% in 2021, then soared 66.01% in 2022.
- Moderna's Enterprise Value stood at -$10.7 billion in 2021, then increased by 7.69% to -$9.9 billion in 2022, then increased by 13.11% to -$8.6 billion in 2023, then increased by 18.35% to -$7.0 billion in 2024, then rose by 17.45% to -$5.8 billion in 2025.
- Per Business Quant, the three most recent readings for MRNA's Enterprise Value are -$5.8 billion (Q4 2025), -$4.5 billion (Q3 2025), and -$5.1 billion (Q2 2025).